Trial reportJournal of the American Academy of Dermatology2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Trial report in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed, 4 syntheses or guidelines pooled it, 330 citations in OpenAlex.
- Pooled it
- Systemic treatments for eczema: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.JAMA dermatology · 2020Pooled it
- Targeted therapy for immune mediated skin diseases. What should a dermatologist know?Anais brasileiros de dermatologiaPooled it
- Trial
- Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.Current therapeutic research, clinical and experimental · 2026Review
- Atopic Dermatitis: New Targets and Emerging Systemic Therapies.American journal of clinical dermatology · 2026Review
- Evaluation of Stress, IL-18, and IL-22 Levels and Their Interrelationships in Patients with Seborrheic Dermatitis.Dermatology practical & conceptual · 2026Article
- Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases.Pharmaceutics · 2026Review
- ANKFN1 in skin fibroblasts may modulate mast cell activity and is associated with dupilumab response in atopic dermatitis.Immunologic research · 2026Article
- The Polygenic Architecture of Human Diseases Affecting the Hair Follicle.The Journal of investigative dermatology · 2026Review
- Heterogeneity in Atopic Dermatitis: Ethnic, Anatomical Site, and Age-related Variations.Clinical reviews in allergy & immunology · 2026Review
- Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria.Dermatology research and practice · 2026Review
- Targeted therapies in atopic dermatitis: toward endotype-driven precision medicine and disease modification.Frontiers in immunology · 2026Review
- Interleukin-24 in type 2 immune diseases.Frontiers in immunology · 2026Review
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.Journal of inflammation research · 2026Review
- Candida albicans Enhances Protease Activity and Activates MyD88-Dependent IL-1β Production in Human Keratinocytes.Mycoses · 2025Article
- Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics.Molecular biomedicine · 2025Review
- Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches.Biomolecules & therapeutics · 2025Review
- Food Sensitization Is Associated With Atopic Dermatitis Severity, Gut-Derived Metabolites and Leaky Gut in Adults.Clinical and translational allergy · 2025Article
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundInterleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function.
objectiveEvaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD).
methodsWe performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point.
resultsAt 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated patients than placebo-treated patients at 12 weeks (21.6 ± 3.8 vs 9.6 ± 4.2, P = .029) and 20 weeks (27.4 ± 3.9 vs 11.5 ± 5.1, P = .010). At 12 weeks, improvements in body surface area involvement in the entire population were significantly stronger in the drug-treated than placebo-treated patients (12.4% ± 2.4 vs 6.2% ± 2.7; P = .009), and in the severe AD subset, the decline in Investigator Global Assessment was significantly higher in the drug-treated than placebo-treated patients (0.7 ± 0.2 vs 0.3 ± 0.1; P = .034). All scores showed progressive improvements after last dosing (10 weeks) until end of study (20 weeks). Common adverse events were upper respiratory tract infections. LIMITATIONS: The limited sample size and lack of assessment with Eczema Area and Severity Index and a pruritus numerical rating scale were limiting factors. Significance was primarily obtained in severe AD.
conclusionFezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.